TRAIL shows potential cardioprotective activity

Investigational New Drugs

Volumn 30, Issue 3, 2012, Pages 1257-1260

  Toffoli, Barbara ^a   Bernardi, Stella ^b   Candido, Riccardo ^d   Zacchigna, Serena ^e   Fabris, Bruno ^f   Secchiero, Paola ^c  

^a INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c UNIVERSITY OF FERRARA   (Italy)

^d ASS 1 Triestina   (Italy)

^e INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^f UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; PARVOVIRUS VECTOR; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; APOLIPOPROTEINS E; APOPTOSIS; CARDIOTONIC AGENTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC CARDIOMYOPATHIES; FIBROSIS; MALE; MICE; MICE, KNOCKOUT; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84864358603     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9627-8     Document Type: Article

References (14)

1. Herbst RS, Eckhardt SG, Kurzrock R et al (2010) Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28:2839-2846
2. Soria JC, Smit E, Khayat D et al (2010) Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 28:1527-1533
3. Secchiero P, Zauli G (2008) TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Op Hematol 15:42-48 (Pubitemid 350191027)
4. Secchiero P, Corallini F, Ceconi C et al (2009) Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PloS One 4:e-4442
5. Niessner A, Hohensinner PJ, Rychli K et al (2009) Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 30:789-796
6. Mori K, Ikari Y, Jono S et al (2010) Association of serum TRAIL level with coronary artery disease. Thromb Res 125:322-325
7. Di Pietro R, Zauli G (2004) Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 201:331-340 (Pubitemid 39453118)
8. Secchiero P, Corallini F, Beltrami PA et al (2010) An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 210:274-277
9. Secchiero P, Candido R, Corallini F et al (2006) Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 114:1522-1530 (Pubitemid 44527008)
10. Milani D, Zauli G, Rimondi E et al (2003) Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 86:126-135 (Pubitemid 36753853)
11. Lipshultz SE, Scully RE, Lipsitz SR et al (2010) Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11:950-961
12. Fabris B, Candido R, Bortoletto M et al (2007) Dose and time-dependent apoptotic effects by angiotensin II infusion on left ventricular cardiomyocites. J Hypertens 25:1481-1490 (Pubitemid 46918837)
13. Candido R, Forbes JM, Thomas MC et al (2003) A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92:785-792 (Pubitemid 36457644)
14. Secchiero P, Zerbinati C, Rimondi E et al (2004) TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61:1965-1974 (Pubitemid 39094803)